Fludrocortisone

Fludrocortisone is a synthetic corticosteroid developed in the early 1950s and introduced into medical practice as one of the first potent mineralocorticoids for therapeutic use. It is primarily used in the treatment of conditions involving aldosterone deficiency, such as Addison’s disease and certain forms of adrenal insufficiency. Its clinical use is based on its strong ability to promote sodium retention and potassium excretion, thereby helping to maintain blood pressure and electrolyte balance. Fludrocortisone became an important part of long-term hormone replacement therapy in patients with adrenal disorders and is often used alongside glucocorticoids like hydrocortisone. Its development represented a significant advancement in endocrine therapy by providing a reliable oral agent with potent mineralocorticoid activity for chronic management of salt-wasting conditions.

BRAND NAMES

Florinef (most widely used international brand)

MECHANISM OF ACTION

Fludrocortisone acts as a potent mineralocorticoid receptor agonist. It mimics aldosterone by acting on the distal tubules and collecting ducts of the kidney, leading to increased sodium and water reabsorption and increased potassium and hydrogen ion excretion. This results in expansion of extracellular fluid volume and elevation of blood pressure, making it useful in conditions of adrenal insufficiency.

PHARMACOKINETICS

Absorption

Fludrocortisone is well absorbed orally and reaches systemic circulation efficiently. It has good bioavailability and begins acting within a few hours after administration.

Distribution

It is widely distributed in body tissues and binds moderately to plasma proteins.

Metabolism

Fludrocortisone is metabolized in the liver via reduction and conjugation pathways, producing inactive metabolites.

EliminationIt is excreted mainly via the kidneys in the form of inactive metabolites. The elimination half-life is approximately 3–4 hours, but biological effects last longer due to receptor binding.

PHARMACODYNAMICS

Fludrocortisone increases sodium retention and potassium loss through mineralocorticoid receptor activation in renal tubules. It helps restore electrolyte balance and maintain blood pressure in patients with adrenal insufficiency or salt-wasting conditions.

ADMINISTRATION

Fludrocortisone is administered orally in tablet form, usually once daily depending on clinical response and electrolyte monitoring.

DOSAGE AND STRENGTH

Dosing is individualized based on blood pressure, serum sodium, and potassium levels. Dose adjustments are often required in long-term therapy.

DRUG INTERACTIONS

Fludrocortisone may interact with diuretics, antihypertensives, and drugs affecting potassium levels, increasing the risk of hypokalemia or fluid imbalance.

FOOD INTERACTIONS

No significant food interactions are known, but sodium intake in diet can influence therapeutic response.

CONTRAINDICATIONS

Contraindicated in patients with systemic fungal infections and caution is required in hypertension, heart failure, and renal impairment.

SIDE EFFECTS

Hypertension
Fluid retention and edema
Hypokalemia
Headache
Weight gain

OVER DOSAGE

Overdose of fludrocortisone results from excessive mineralocorticoid activity, leading to significant fluid and electrolyte disturbances. The most important effects include sodium and water retention, causing hypertension, edema, and weight gain, along with marked potassium loss (hypokalemia).

TOXICITY

Overdose of Fludrocortisone leads to excessive mineralocorticoid effects such as severe hypertension, fluid overload, edema, and marked hypokalemia, which may cause muscle weakness, arrhythmias, and metabolic alkalosis. Management includes stopping the drug, correcting electrolytes (especially potassium), restricting sodium intake, and using antihypertensive therapy if needed. Severe cases may require medical monitoring and supportive care.